仿真模拟教学在脊髓损伤患者间歇导尿操作中应用探索

目的:探索仿真模拟教学在脊髓损伤患者/家属实施自主导尿操作的临床效果。方法:将我科2017年5月~2017年12月收治72例脊髓损伤致神经源性膀胱患者按随机数字表法分为观察组38例和对照组34例,对照组采用常规方法,观察组采用仿真模拟教学,由护士对患者/家属进行导尿操作培训,患者/家属操作熟练后方可行导尿操作,比较两组患者/家属清洁间歇导尿操作掌握情况、培训满意度、导尿成功情况、干预前后日常生活能力及生存满意度改变情况。结果:观察组对于仿真模拟教学满意度高,培训后导尿操作成功率高,且患者日常生活能力及生存满意度显著高于对照组,差异有统计学意义(P<0.05)。结论:在间歇导尿操作培训中对患者/家属应用仿真模拟教学方法有利于提高其导尿操作熟练度,提高导尿成功率,增加患者的满意度,值得临床推荐。     

2014—2018年黄山市淋病疫情流行特征分析

目的分析2014-2018年黄山市淋病的流行特征,为全市的淋病防控工作提供科学依据。方法通过中国疾病预防控制信息系统收集黄山市2014—2018年的淋病数据、人口数据,进行统计分析。结果2014—2018年黄山市累计报告淋病病例761例,年均发病率为11.09/10万,年均增长率为29.14%,发病率呈逐年上升趋势(χ^2趋势=112.29,P<0.05)。淋病的人群分布中,男女报告病例数之比为13.63:1,男女发病率有统计学差异(χ^2=113.18,P<0.05);15~49岁年龄组病例数最多,占85.94%,职业以农民最多,占44.81%;以屯溪区、歙县报告病例数较多,分别占37.45%、23.26%。结论2014—2018年黄山市淋病发病率呈上升趋势,淋病防控形势严峻,需进一步完善各项防控措施。     

欧洲、澳大利亚、英国生殖支原体感染诊疗指南介绍

【摘要】 生殖支原体可导致非淋菌性尿道炎、宫颈炎等泌尿生殖道感染甚至附睾炎、盆腔炎、早产等并发症。由于近年来生殖支原体感染率的升高以及多种常用治疗药物耐药的普遍出现，2016年欧洲、2017年澳大利亚性健康联盟、2018年英国性健康与HIV协会分别颁布了生殖支原体感染的诊疗指南，就其感染的临床表现、诊断、患者与性伴的治疗、随访等方面给出了建议，对我国生殖支原体感染的诊治有重要的指导意义。     

Cerebroprotective Potential of Hesperidin Nanoparticles Against Bilateral Common Carotid Artery Occlusion Reperfusion Injury in Rats and In silico Approaches

Neurotoxicity Research - Cerebral ischemia-reperfusion (C I/R) accelerates neuronal injury through the overproduction of reactive oxygen species due to mitochondrial dysfunction. Hesperidin has...     

卒中偏瘫患者出院后习得性废用发展情况的调查研究

目的 调查卒中亚急性期偏瘫患者出院后习得性废用发展情况，分析习得性废用与患者人口学因素、 临床特点及功能恢复的相关性。 方法 前瞻性连续纳入2018年7月-2019年12月期间南方医科大学深圳医院预备出院的卒中偏瘫患 者。收集患者一般资料和临床特点，并在出院后4周、8周和12周用运动活动记录表（motor activity log， MAL）评估患者的习得性废用情况，在出院前3 d，出院后4周、8周和12周用改良Ashworth指数测试肘 腕屈肌群肌张力，偏瘫上肢功能测试香港版、Fugl-Meyer评定量表上肢部分和箱块测试评价上肢功 能，功能独立性评定评价日常生活能力。对各随访时间点MAL与其他评估量表、人口学因素和临床特 点进行相关性分析。 结果 研究完成随访患者47例，男性36例（76.6%），平均年龄58.74±11.08岁，平均发病时间 48.00±28.38 d，其中缺血性卒中32例（68.1%），出血性卒中15例（31.9%）。MAL的患手使用频率/ 患者活动质量在出院后4周、8周和12周时分别为2.66（1.38～4.03）分/2.87（1.03～3.56）分、3.30 （1.93～4.41）分/3.17（1.55～3.77）分和3.59（2.00～4.33）分/3.28（2.00～3.96）分，除8周与12周 之间的患手使用频率差异无统计学意义之外，其他时间点之间差异均具有统计学意义。各随访时间 点患者肘屈肌群张力变化差异无统计学意义（P =0.076），其余功能表现均显著恢复（均P <0.05）。出 院后4周、8周和12周各时间点，MAL与年龄呈一般正相关（ρ=0.33～0.39），与发病时间呈一般负相关 （ρ=-0.49～-0.33），与肘腕部屈肌张力呈一般至中等负相关（ρ=-0.58～-0.38），与日常生活能力 呈一般至中等正相关（ρ=0.30～0.60），与上肢运动功能呈一般至强正相关（ρ=0.49～0.76）。 结论 卒中亚急性期偏瘫患者出院后患肢仍然可以保持显著的功能恢复，但依然面临习得性废用 的挑战，且习得性废用与年龄、发病时间、腕肘屈肌群张力、日常生活生活能力和上肢功能相关。     

A Phase I Dose Escalation Study of the Safety,Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Patients with Select Advanced Solid Tumors

Lessons Learned

• The overall safety profiles of ipilimumab 3 mg/kg and 10 mg/kg administered every 3 weeks, were consistent between Chinese patients with solid tumors in the current study and patients from previous U.S. ipilimumab monotherapy studies. No new safety signals were identified.
• The mean systemic exposures to ipilimumab (assessed by first dose area under the curve during the dosing interval and maximum serum concentration) were numerically lower in the Chinese patient population than in U.S. patients for both 3 mg/kg and 10 mg/kg doses; however, the range of serum concentrations in the Chinese and U.S. populations overlapped (3 mg/kg and 10 mg/kg), suggesting that ipilimumab pharmacokinetics was ethnically insensitive in this study.

BackgroundThis phase I, open‐label study assessed ipilimumab safety, tolerability, pharmacokinetics (PK), immunogenicity, and antitumor activity in Chinese patients with unresectable, metastatic, recurrent malignant melanoma (MM) or nasopharyngeal carcinoma (NPC).MethodsOf 39 patients enrolled, 25 received ipilimumab (11 patients received 3 mg/kg, and 14 patients received 10 mg/kg). Reasons for not receiving treatment were withdrawal of consent (3 patients), no longer meeting the criteria (10 patients), and one recorded as “other.” During the induction phase, patients received ipilimumab (3 mg/kg, i.v.), on day 1 of a 3‐week cycle, to a maximum of four doses or progressive disease (PD). During the maintenance phase at week 24, patients received ipilimumab (3 mg/kg, i.v.) on day 1 of a 12‐week cycle, to a maximum of 3 years or PD. Considering the co‐primary safety and PK endpoints, the successive dosing required nine patients with two or fewer dose‐limiting toxicities during the 42‐day observation period to proceed with a new cohort of nine patients at 10 mg/kg.ResultsIpilimumab safety and PK profiles were similar in Chinese and predominantly White populations. Ipilimumab was well tolerated. Most adverse events (AEs) were grades 1–2 and experienced by 11 patients treated with 3 mg/kg and 14 patients treated with 10 mg/kg. There were no new safety concerns. Incidence of anti‐ipilimumab antibodies was low (1 of 10 in the 3 mg/kg patients and 2 of 13 in the 10 mg/kg patients) and without safety implications. In the 3 mg/kg group, 8 of 11 patients had PD. In the 10 mg/kg group (all NPC, 0 MM patients), 11 of 14 patients had PD. Three patients had stable disease (one at 3 mg/kg and two at 10 mg/kg).ConclusionIpilimumab was well tolerated in Chinese patients, showing similar safety and PK to previous studies in predominantly White populations.     

Retraction notice for Long-term outcomes of 530 esophageal squamous cell carcinoma patients with minimally invasive Ivor Lewis esophagectomy. J Surg Oncol. 2018; 117:957-969

Long-term outcomes of 530 esophageal squamous cell carcinoma patients with minimally invasive Ivor Lewis esophagectomy. J Surg Oncol. 2018; 117:957-969. https://doi.org/10.1002/jso.24997 The above article, published online on May 30, 2018 in Wiley Online Library ( wileyonlinelibrary.com ), has been retracted by agreement between the authors and the Journal Editor in Chief Dr. Stephen Sener and Wiley Periodicals, Inc. The retraction has been agreed following concerns raised that the number of patients operated on was considerably lower than the number of patients reported in the article. When asked to provide documentary evidence of the operations performed, the authors confirmed the reported discrepancy and requested to retract their article.